Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation. 1998

F Citterio, and P Torricelli, and F Serino, and M Foco, and U Pozzetto, and P Fioravanti, and M Castagneto
Department of Surgery, Catholic University, C.N.R., Rome, Italy.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400
D016903 Drug Monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug

Related Publications

F Citterio, and P Torricelli, and F Serino, and M Foco, and U Pozzetto, and P Fioravanti, and M Castagneto
January 2001, Clinical transplantation,
F Citterio, and P Torricelli, and F Serino, and M Foco, and U Pozzetto, and P Fioravanti, and M Castagneto
November 2002, Hinyokika kiyo. Acta urologica Japonica,
F Citterio, and P Torricelli, and F Serino, and M Foco, and U Pozzetto, and P Fioravanti, and M Castagneto
November 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
F Citterio, and P Torricelli, and F Serino, and M Foco, and U Pozzetto, and P Fioravanti, and M Castagneto
October 2002, Medizinische Klinik (Munich, Germany : 1983),
F Citterio, and P Torricelli, and F Serino, and M Foco, and U Pozzetto, and P Fioravanti, and M Castagneto
December 2017, Journal of nephrology,
F Citterio, and P Torricelli, and F Serino, and M Foco, and U Pozzetto, and P Fioravanti, and M Castagneto
August 1998, Transplantation proceedings,
F Citterio, and P Torricelli, and F Serino, and M Foco, and U Pozzetto, and P Fioravanti, and M Castagneto
April 1994, Transplantation proceedings,
F Citterio, and P Torricelli, and F Serino, and M Foco, and U Pozzetto, and P Fioravanti, and M Castagneto
July 2021, Transplantation,
F Citterio, and P Torricelli, and F Serino, and M Foco, and U Pozzetto, and P Fioravanti, and M Castagneto
December 2015, Clinical journal of the American Society of Nephrology : CJASN,
F Citterio, and P Torricelli, and F Serino, and M Foco, and U Pozzetto, and P Fioravanti, and M Castagneto
August 2018, Transplantation direct,
Copied contents to your clipboard!